GlassScriptPhysician profile
Siva K Mannem
NPI 1073822235
$53,018.50
in general payments reported to CMS, 2019-2025
28 companies · $792 in 2025
The $792 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,007 · 2020: $6,852 · 2021: $1,163 · 2022: $11K · 2023: $18K · 2024: $6,919 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $2,793 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Food and Beverage: $388 · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,579.25 |
| Travel and Lodging | $2,792.69 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Food and Beverage | $387.53 |
| Education | $378.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $13,699.14 | 2019-2025 | Adcetris |
| Kite Pharma, INC. | $7,517.71 | 2020-2023 | Tecartus |
| Incyte Corporation | $6,539.76 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $4,108.94 | 2019-2024 | Imfinzi, Calquence |
| Amgen INC. | $3,912.11 | 2019-2020 | |
| Celgene Corporation | $3,591.53 | 2019 | |
| Beigene USA, INC. | $3,550.00 | 2022-2024 | Brukinsa, Tevimbra |
| Abbvie INC. | $1,800.00 | 2020 | |
| Cti Biopharma Corp. | $1,725.00 | 2023 | Vonjo |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Aveo Pharmaceuticals, INC. | $1,365.00 | 2023 | Fotivda |
| Morphosys, US INC. | $1,151.30 | 2021 | |
| Glaxosmithkline, LLC. | $1,150.00 | 2020 | |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Astellas Pharma US INC | $281.97 | 2022-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $138.02 | 2022-2024 | Opdualag, Opdivo |
| Agios Pharmaceuticals, INC. | $119.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.09 | 2025 | |
| Eisai INC. | $28.99 | 2024-2025 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Keytruda |
| Alexion Pharmaceuticals, INC. | $15.00 | 2024 | Ultomiris |
| Gilead Sciences, INC. | $11.92 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siva Mannem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.